Kornimate/medical-research-clean huggingface dataset:
psychological and psychiatric profile in glioblastoma and head and neck cancer

Conditions: Glioblastoma; Head and Neck Cancer

Summary: approximately 30% of cancer patients may experience psychopathological disorders. the most common psychopathological disorders in cancer patients are mood disorders, anxiety, depression, adjustment disorders, and suicidal ideation. among depressive disorders, mixed depression, with the simultaneous presence of symptoms of both depressive and manic polarity, is associated to higher levels of chronicity, functional impairment and suicidality. these disorders can also be worsened by loneliness and demoralization. patients with head and neck cancer (h\&n-c) and glioblastoma multiforme (gbm) have high psychological and sometimes psychiatric comorbidity probably due to the severity, poor prognosis of these cancers and harsh treatment toxicities. the most important protective factor for psychopathology is psychological resilience, which is "the capacity of a person to protect themselves and their mental health when facing life adversities," such as a gbm or h\&n-c diagnosis. resilience is influenced by the affective temperament, which refers to basic personality traits related to behavioral and emotional reactivity to environmental stimuli. it is believed to be biologically determined and relatively stable throughout life. to date, the literature does not clarify the role of resilience and temperament in mediating the psychological profile of cancer patients. furthermore, extensive profiling of the psychological and psychiatric profile of these patients at such a critical and pivotal moment in their journey is currently lacking in the literature. aim of this study is to evaluate global psychological and psychiatric profile of patients affected by gbm and h\&n-c and the eventual fluctuation over time during rt course. conducting an early and accurate screening for potential psychopathological issues will give the opportunity to avoid factors that could: worsen patient compliance, lead to suicidal risk, and increase hospitalizations. the results obtained will be utilized for planning precocious psychological or psychiatric take-in-charge aimed at promoting psychological well-being of h\&n-c and gbm patients.


Eligibility criteria:
inclusion criteria: * consecutive glioblastoma and head and neck cancer patients undergoing a long course of radiotherapy * patients in adjuvant rt * patients in radiotherapy plus chemotherapy (rtct) adjuvant regimen * ability to understand and complete the questionnaires * age \> 18 years * informed consent signed exclusion criteria: * age \> 75 years * glioblastoma and head and neck cancer patients undergoing palliative radiotherapy * patients with inability to express informed consent * patients denying informed consent * patients affected by severe language deficits
wf and pr octa in diabetic retinopathy

Conditions: Diabetic Retinopathy

Summary: diabetic retinopathy (dr) is a leading cause of vision loss in working-age americans. capillary damage from hyperglycemia causes vision loss through downstream effects, such as retinal ischemia, edema, and neovascularization (nv). proper screening and timely treatment with laser photocoagulation and anti-vascular endothelial growth factor (vegf) injections can minimize morbidity. in the last decade, clinicians have been able to use objective structural data from optical coherence tomography (oct) to guide the treatment of diabetic macular edema. other aspects of care, however, still largely depend on subjective interpretation of clinical features and fluorescein angiography (fa) to determine the disease severity and treatment threshold. the recently developed oct angiography (octa) provides dye-less, injection-free, three-dimensional images of the retinal and choroidal circulation with high capillary contrast. not only is it safer, faster, and less expensive than conventional dye-based angiography, octa provides the potential of giving clinicians objective tools for determining severity of disease by detecting and quantifying nv and non-perfusion.


Eligibility criteria:
participant-related inclusion criteria: i. all diabetics (groups a, b, c) * type 1 diabetes of at least 5 years duration or * type 2 diabetes of any duration ii. group b * able to return for follow-up over 3 years participant-related exclusion criteria: i. group b * significant medical condition that would make long-term follow-up difficult ii. controls (group d) * any medical problems associated with retinal vascular abnormalities (i.e., hypertension, systemic vasculitis, carotid insufficiency, etc.) eye-related inclusion criteria: i. group a: * presence of active neovascularization, with or without prior treatment * presence of involuted fibrovascular proliferans ii. group b: * npdr of any severity as defined by the international clinical diabetic retinopathy severity scale iii. groups c \& d: * no evidence of diabetic retinopathy iv. group me: * presence of center-involving macular edema requiring treatment eye-related exclusion criteria: (applies to study eye only. may be present in non-study eye.) * visual acuity worse than 20/200 * inability to maintain stable fixation for oct imaging * history of major eye surgery (vitrectomy, cataract surgery, scleral buckle, other intraocular surgery, etc.) within 90 days of enrollment * history of another eye disease or condition that may alter retinal perfusion, permeability, or retinal anatomy * substantial media opacity (cataract, corneal scar, vitreous hemorrhage) that may interfere with study imaging

Keywords: diabetes oct angiography diabetic retinopathy
improving aspirin use among adults at risk for cardiovascular disease (cvd)

Conditions: Cardiovascular Disease

Summary: the investigators' aim is to implement an intervention to increase aspirin prophylaxis use among patients that is patient initiated, optimizes use of physician and staff time, appropriately compensates staff, provides clinicians with tools necessary for managing aspiring prophylaxis, and ensures continuous management.

this intervention addresses a fundamental question of how clinicians need to be directly involved in motivating behavior change (i.e., aspirin prophylaxis). while complex behavior change likely demands high levels of involvement, a single simple action (aspirin prophylaxis) may not require such complex interactions. we propose to compare the effectiveness of three models of care in a rigorous randomized controlled trial that will consist of a 3-arm, within-clinic design in which patients will be randomized to either the physician-initiated, the patient-initiated model, or to a control group in which usual care is delivered. in a patient-initiated model, patients are active participants in their own care and receive a pre-visit summary that contains an individualized risk assessment and patient education. in the physician-initiated model, patients receive the pre-visit summary and the physician uses a clinical decision support tool through the electronic health record that details the patient risk of cvd. the specific aims of the proposed work are to compare the reliability and overall effectiveness of two different methods for motivating patients to take aspirin to prevent stroke and heart attacks as well as to develop a plan for translating the intervention into a process that is suitable for a paper-based clinic.

Eligibility criteria:
inclusion criteria: patients with an appointment in the geisinger clinic who: * are between the ages of 45-70 (male) or 50-70 (female), and * have one of the following risk factors: 1. smoke 2. direct ldl \> 160 mg/dl 3. hdl \< 45 mg/dl (males) hdl \< 35 mg/dl (females) 4. diabetes diagnosis 5. hypertension diagnosis 6. cad diagnosis exclusion criteria: * \> 70 years * stomach ulcer history * aspirin allergy * anti-coagulation therapy history * clotting disorder diagnosis * hypersensitivity to non-steroidal anti-inflammatory agents such as ibuprofen, aleve, or motrin * hemorrhagic stroke history * current aspirin use * 1st outpatient visit

Keywords: aspirin behavior cardiovascular disease
effect of multisensory motor imagery training on muscle performance and coordination in children with spastic diplegia

Conditions: Spastic Diplegia; Motor Imagery

Summary: purpose: the current study aims to: * determine the effect of multisensory motor imagery training on muscle performance including (peak torque, work, power) of trunk and knee flexors and extensors in children with spastic diplegia. * determine the effect of multisensory motor imagery training on coordination, strength and agility in children with spastic diplegia. background: multisensory motor imagery training has an effect on muscle performance and coordination in children with spastic diplegia hypotheses: there will be no effect of multisensory motor imagery training on muscle performance, coordination and strength and agility in children with spastic diplegic cp. research question: is there an effect of multisensory motor imagery training on coordination, strength and agility in children with spastic diplegia?


Eligibility criteria:
inclusion criteria: * their age will be ranged from 8-12 years. * mild degree of spasticity ranged from 1 to 1+ according to modified ashworth scale * their motor function will be at level i and ii according to gross motor function classification system gmfcs * they will be able to follow instructions during evaluation and treatment. exclusion criteria: * - cardiovascular or respiratory disorders. * botulinium muscular injection in the last 6 months * surgical interference in lower limbs and/or spine. * muscloskeletal problems or fixed deformities in the spine and/or lower extremities. * seizures. * visual or hearing impairment
a safety, tolerability and pharmacokinetic study of nd0611 on the top of different oral dosage forms of levodopa/carbidopa in parkinson's disease patients

Conditions: Parkinson's Disease

Summary: a cross-over study, where nd0611 or placebo will be tested on top of 3 different ld/cd dosage forms. safety and tolerability, pharmacokinetic profile of levodopa and carbidopa and the potential clinical effect of nd0611 will be explored in subjects with pd and motor fluctuations.


Eligibility criteria:
inclusion criteria: 1. men and women with idiopathic parkinson's disease 2. subjects must experience motor fluctuations associated with ld/cd dosing 3. modified hoehn and yahr stage \< 5 4. subjects must be taking optimized and stable levodopa/dopa decarboxylase inhibitor therapy 5. women must be postmenopausal, surgically sterilized, or using adequate birth control. women of childbearing potential must have a negative pregnancy test (serum beta-hcg) at screening. 6. subjects must be age 30 or older. 7. subjects must be willing and able to give informed consent. exclusion criteria: 1. subjects with a clinically significant or unstable medical or surgical condition 2. subjects with clinically significant psychiatric illness. 3. pre-menopausal women, not using birth control method. 4. subjects who have taken experimental medications within 60 days prior to baseline. 5. subject who have undergone a neurosurgical intervention for parkinson's disease (e.g., pallidotomy, thalamotomy, transplantation and deep brain stimulation).

Keywords: motor fluctuations levodopa pharmacokinetics carbidopa solution continuous
propolis extract, nanovitamin c and nanovitamin e in peri-implant mucositis

Conditions: Peri-implant Mucositis

Summary: the objective of this study was to perform the first clinical trial to evaluate the effectiveness of propolis extract, nanovitamin c and nanovitamin e gel as adjuvant to mechanical debridement in clinical and microbiological parameters of implants with peri-implant mucositis


Eligibility criteria:
inclusion criteria: * cooperative adult patients, * with one or more implants with peri-implant mucositis, and * presenting at least 18 months of functional loading. exclusion criteria: * refuse to participate in the study, * patients who had implants with peri-implantitis (bop and/or suppuration together with progressive radiographic marginal bone loss), * patients with uncontrolled periodontitis (presence of nine or more sites with pd ≥ 5 mm and with full-mouth bleeding score (fmbs) \> 25%), * systemic diseases or conditions that could alter the results of the study (diabetes mellitus, immunosuppression, infectious diseases, rheumatoid disease, history of bisphosphonate treatment, radiotherapy, chemotherapy, etc.), * patients who had taken local and/or systemic antibiotics less than 2 months ago, * pregnant or breastfeeding women, and * patients with history of allergies to the test and/or placebo components administered.

Keywords: dental implants peri-implant mucosits toothpaste propolis nanovitamin
approach to a quantitative follow-up of non-thyroidal illness syndrome

Conditions: Euthyroid Sick Syndromes; Non-thyroidal Illness Syndrome; Low T3 Syndrome; TACITUS

Summary: aqua fontis is a unicentric, multidisciplinary, prospective cross-section and longitudinal study that aims at the development of a more clear-cut diagnostic definition and classification of non-thyroidal illness syndrome (ntis).

detailed description: non-thyroidal illness syndrome (ntis), also referred to as euthyroid sick syndrome (ess) or thyroid allostasis in critical illness, tumors, uremia and starvation (tacitus), is a complex endocrine condition that may occur in critically ill patients. it is associated with significantly increased morbidity and mortality. ntis is characterised by three components that may occur single or in combination: 1. central hypothyroidism (transient thyrotropic insufficiency) 2. impaired protein binding of thyroid hormones and 3. reduced formation of t3 and increased conversion to rt3 (low-t3-syndrome). despite of long lasting research to some of its details ntis is still poorly characterized in an integrative view. additionally, it lacks a clinically usable classification. given the fact that patients with ntis are faced with poor prognosis, several studies have been conducted in the past evaluating the question of possible treatment. however, they didn't yield unambiguous results, maybe due to the fact that these studies did not differentiate among the distinct components of ntis. therefore, this study is intended to develop a clear-cut definition and classification of ntis in order to set a foundation for future therapeutic studies. this study recruits critically ill patients treated in medical and surgical intensive care units of the bergmannsheil university hospitals for evaluation of integrative thyrotropic control and follow-up. from these data the correlation of individual prognosis with laboratory-defined components of ntis will be determined. this project is intended to: 1. deliver a prognostical aid by providing a differentiated classification, 2. to contribute to a standardised, rational and inexpensive diagnostical procedure and 3. to lay the foundation for future therapeutic trials by identifying subgroups that may benefit from therapy.

Eligibility criteria:
inclusion criteria: * severe illness requiring intensive care * stay of at least 24 hours at the icu exclusion criteria: * substituted hypothyroidism or substitution in case of thyroid carcinoma * hyperthyroidism that is treated with thyrostatic agents and exhibits a ths level not below the reference region * manifest aids disease

Keywords: critical illness euthyroid sick syndromes intensive care non-thyroidal illness syndrome low-t3 syndrome
phase 1 study of aurora kinase inhibitor pf-03814735 in patients with advanced solid tumors

Conditions: Solid Tumors

Summary: the purpose of this study is to determine the maximum tolerated dose and recommended phase 2 dose of pf-03814735 administered orally as single agent in patients with advanced solid tumors.


Eligibility criteria:
inclusion criteria: * metastatic solid tumor resistant to standard therapy or for which no standard therapy is available * adequate bone marrow, liver and kidney function exclusion criteria: * brain metastases that are symptomatic and/or require treatment with steroids and/or anticonvulsants, or brain metastases that have been treated within 3 months prior to study start * myocardial infarction, severe/unstable angina, symptomatic congestive heart failure, cerebrovascular accident in the previous 6 months
virtual reality for panic disorder with agoraphobia

Conditions: Panic; Agoraphobia

Summary: panic disorder with agoraphobia (pda) is associated with considerable personal distress, functional disability and societal costs. a large number of studies have shown that cognitive behavior therapy (cbt) is a highly effective treatment for pda. however, the cbt-protocols proven to be most effective involves repeated exposure to the particular environments the agoraphobic patient fears such as trains, tunnels, lifts and shops. this cause great practical problems for health care services as such therapeutic efforts involves spending considerable time outside the clinic. for primary care services this is particularly challenging due to the large number of patients expected to be seen. normally clinicians meet up to 7 patients daily which makes it almost practically impossible to offer 2-hour sessions, which is necessary to carry out the relevant exposure tasks. hence, the treatment proven to be most effective, which primary care services are commissioned to deliver, is too comprehensive and time consuming to be applied in real practice. the investigators believe that a possible solution to the above problem is to provide evidence-based cbt but with the exposure components carried out through virtual reality (vr) rather than in vivo. some research has already been done with virtual reality and exposure therapy for anxiety disorders with promising results. the aim of this pilot study is to treat patients with agoraphobia with or with a history of panic disorder with a standardized exposure-based cbt-protocol through vr. the virtual environments that are used for the study are live sequences filmed in 360°. the investigators hypothesize that cbt with vr will be effective and lead to improvements on measures of panic disorder and agoraphobia.


Eligibility criteria:
inclusion: * a primary diagnosis of agoraphobia with or with a history of panic disorder according to the diagnostic and statistical manual of mental disorders 5 (dsm-5). * minimum 18 years of age. * able to read and write in swedish exclusion: * other primary axis-i disorder * ongoing substance abuse or addiction * current or previous episode of psychosis or bipolar disorder * severe major depressive disorder: * moderate to severe suicidal risk * non-stable antidepressant medication (changed during the last month) or not agreeing to keep dosage constant throughout the study * ongoing concurrent psychological treatment * having received previous high quality cognitive therapy or cognitive behavior therapy for agoraphobia during the recent year
teg (thromboelastography) based versus conventional coagulation parameters based correction of coagulopathy in non variceal bleed.

Conditions: Non Variceal Bleed

Summary: all patients with non variceal bleed who are admitted under the department of hepatology at institute of liver and biliary sciences, who meet the inclusion criteria and who provide informed consent.


Eligibility criteria:
inclusion criteria: * age more than 18 * all patient with non variceal bleed (inr\>1.8 and platelets\<50000) * hist logical or imaging proven liver cirrhosis. exclusion criteria: 1. variceal bleed, 2. pregnancy., 3. patients on anticoagulation 4. patients who refused to participate in the study 5. post evl ulcer bleed
black tea compresses for facial eczema and perioral dermatitis

Conditions: Eczema, Dermatitis

Summary: facial eczema and perioral dermatitis are clinical entities that develop exclusively in the face and present a special therapeutic challenge. topical corticosteroids that are commonly applied to treat eczema/dermatitis at other body sites are best avoided in the face, as they may result in rapid atrophy of facial skin and in the long term rather aggravate facial dermatoses. black tea compresses have been successfully used by german-speaking dermatologists to treat facial eczema/dermatitis for decades. the precise mechanism of action is unknown but is presumably based on astringent properties of tannins in the black tea and on the antiinflammatory action of a wet compress as such. this therapy is cheap, universally available and practically free of side-effects. despite these perceived advantages the effects and tolerance of black tea compresses have not been formally studied to date. therefore, the investigators plan to treat 25 patients with facial eczema/perioral dermatitis over a period of 6 days each within the current trial. the disease activity will be assessed before, during and after completion of treatment using several clinical scores. in addition, side-effects, if any, will be documented.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of facial eczema or perioral dermatitis * minimum age of 18 years * patient is capable of granting informed consent * patient is expected to comply with the trial treatment protocol * for outpatients: close place of residence exclusion criteria: * initiation or increase of systemic immunosuppressive or antibiotic treatment necessary * psychiatric disease or other factors making poor patient compliance probable * participation in another clinical trial within the past 6 months
clopidogrel reloading in clopidogrel resistant patients with acs

Conditions: Clopidogrel Non-Responsiveness

Summary: laboratory clopidogrel resistance is associated with adverse atherothrombotic events in patients with coronary artery disease. in the proposed study we wish to prospectively assess the effect of reloading with 600 mg clopidogrel, and administer maintenance treatment with clopidogrel 150 mg/day for one month in a group of acute myocardial infarction (ami) patients who demonstrate non-responsiveness to clopidogrel.

prior studies have demonstrated significant variability in platelet response to clopidogrel in patients with coronary artery disease (cad). up to 25% of patients have been shown to be non-responders to a conventional dose of clopidogrel. this phenomenon has been associated with higher incidence of recurrent cardiovascular (cvs) adverse events in patients with acute coronary syndrome (acs), and higher incidence of peri-procedural myocardial damage, thrombotic complications, and ischemic events in patients undergoing elective percutaneous coronary intervention (pci). both the ex-vivo anti-platelet effect and the clinical benefit of clopidogrel are dose related. moreover, in patients sustaining acs while on maintenance clopidogrel treatment, reloading with 600 mg clopidogrel, resulted in further reduction in platelet aggregation, although the patients were not non-responders. despite this, the effect of dose escalation has never been examined in patients resistant to clopidogrel. in the present study we wish to assess prospectively the effect of reloading with 600 mg clopidogrel, and double dose maintenance treatment (150 mg/day) for one month in acute myocardial infarction (ami) patients who demonstrate non-respondese to clopidogrel.

Eligibility criteria:
inclusion criteria: * age equal or over 18 years * acute coronary syndrome * clopidogrel non-responsive * signed an informed consent exclusion criteria: * bleeding disorder * hypersensitivity to aspirin or clopidogrel * any contraindication to anti-thrombotic or anticoagulant therapy * active neoplastic disorder

Keywords: clopidogrel platelets acute coronary syndrome percutaneous coronary intervention